Thomas Andrew Crockett - 17 Nov 2023 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role: CEO, Director
Signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol: KALV
Transactions as of: 17 Nov 2023
Net transactions value: -$121,851
Form type: 4
Filing time: 21 Nov 2023, 16:30:10 UTC
Previous filing: 01 Nov 2023
Next filing: 28 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KALV	Common Stock	Options Exercise		+33,583	+24%		172,339	17 Nov 2023	Direct	F1
transaction	KALV	Common Stock	Sale	$121,851	-14,807	-8.6%	$8.23	157,532	20 Nov 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KALV	Restricted Stock Unit	Options Exercise	$0	-6,945	-11%	$0.000000	55,556	17 Nov 2023	Common Stock	6,945		Direct	F1, F3
transaction	KALV	Restricted Stock Unit	Options Exercise	$0	-5,805	-9.1%	$0.000000	58,050	17 Nov 2023	Common Stock	5,805		Direct	F1, F4
transaction	KALV	Performance Stock Unit	Options Exercise	$0	-20,833	-100%	$0.000000^*	0	17 Nov 2023	Common Stock	20,833		Direct	F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2	The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs and performance stock units ("PSUs"). The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3	1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 17, 2022, for a period of three years, subject to continued service through each vesting date.
F4	1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, subject to continued service through each vesting date.
F5	Each PSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F6	Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on June 8, 2023. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of Performance Data and Enrollment Metrics goals ("Performance Metrics"). 1/4th of the total number of shares subject to the PSU shall vest on each quarterly anniversary of the Vesting Commencement Date of November 17, 2023, upon Performance Metrics achieved, subject to continued service through each vesting date.